Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

Arsenic trioxide (ATO)-based regimens are the standard of care for treating acute promyelocytic leukaemia (APL) and have replaced chemotherapy-based approaches. However, the cost of “patented” ATO is prohibitive because of patent rights. “Generic” ATO has been used in a few countries, but its implic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Haematol
Autori principali: Bankar, Aniket, Korula, Anu, Kulkarni, Uday P., Devasia, Anup J., Fouzia, NA, Lionel, Sharon, Abraham, Aby, Balasubramanian, Poonkuzhali, Janet, Nancy Beryl, Nair, Sukesh C., Sezlian, S, Jeyaseelan, Visali, Jeyaseelan, N, Prasad, Jasmine, George, Biju, Mathews, Vikram
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7617145/
https://ncbi.nlm.nih.gov/pubmed/31863602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16343
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi